ClinicalTrials.gg
CompletedNCT00846365Updated Mar 13, 2012Results posted

Efficacy and Safety of Azilsartan Medoxomil Plus Chlorthalidone in Participants With Moderate to Severe Hypertension

A Phase 3 interventional study of Azilsartan medoxomil and chlorthalidone and Azilsartan medoxomil and chlorthalidone in Essential Hypertension, sponsored by Takeda. Completed at 80 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-03-13.

Sponsored by Takeda · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,085
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies testing azilsartan medoxomil in Essential Hypertension — none open to participants now, none under way, none of them phase 3. azilsartan medoxomil · Essential Hypertension.

Enrollment
3rd of 11
1,085 · median 837
Started
2009
with 2 others
Phase 3
10 of 11
none open now
Registered
7th of 11
by date
Lead sponsor
11 of 11
Takeda

Among the 11 studies testing azilsartan medoxomil in Essential Hypertension, this one is the 3rd largest by enrollment, is one of 3 that started in 2009, is one of 10 in phase 3, and was the 7th registered.

Essential Hypertension

480 studies on the registry are indexed under Essential Hypertension; 76 are open to participants now.

Browse Essential Hypertension studies →

Open to participants now

None of the 11 studies testing azilsartan medoxomil in Essential Hypertension is open now. The open studies under Essential Hypertension, anywhere →

About azilsartan medoxomil

azilsartan medoxomil: first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 45 Essential Hypertension studies recruiting now, 17 (38%) set no upper age limit and 20 (44%) stop at 75 or younger; 4 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies testing azilsartan medoxomil in Essential Hypertension as a file.
02

Study summary

The purpose of this study is to determine the efficacy and safety of azilsartan medoxomil combined with chlorthalidone, once daily (QD), in participants with moderate to severe essential hypertension.

Read the detailed description

According to the World Health Organization, hypertension is the most common attributable cause of preventable death in developed nations, as uncontrolled hypertension greatly increases the risk of cardiovascular disease, cerebrovascular disease and renal failure. As the population ages, the prevalence of hypertension will continue to increase if broad and effective preventive measures are not implemented. Despite the availability of antihypertensive agents, hypertension remains inadequately controlled; only about one-third of patients continue to maintain control successfully.

Although most antihypertensive agents are effective at the appropriate dose, the majority have side effects that limit their use. As a class, angiotensin II receptor blockers generally are considered more tolerable than other classes of antihypertensive agents. TAK-491 (azilsartan medoxomil) is an angiotensin II receptor blocker being evaluated by Takeda to treat essential hypertension.

Treatments for essential hypertension commonly include use of a thiazide-like diuretic, either alone or as part of combination treatment. Although chlorthalidone was commonly prescribed in the past, its use has widely been replaced with hydrochlorothiazide, presumably due to a lack of available combination products containing chlorthalidone, the assumption that hydrochlorothiazide and chlorthalidone have similar antihypertensive effects and cardiovascular benefits, and the perception that chlorthalidone use is associated with a greater frequency of hypokalemia. However, the frequency of hypokalemia with chlorthalidone use is relatively low in the dose range of 12.5 to 25 mg and these doses have been shown to be associated with potent blood pressure reduction. Several long-term outcomes trials have shown that blood pressure reductions associated with chlorthalidone treatment reduce risk of cardiovascular morbidity and mortality.

Most hypertensive patients require two or more agents to achieve target blood pressure and diuretics are commonly used in combination with other antihypertensive agents.

Participants in this study will be randomized to receive one of 3 possible dosing combinations of azilsartan medoxomil with either chlorthalidone or olmesartan medoxomil-hydrochlorothiazide over 8 weeks. The total duration of the study is approximately 13 weeks. Participants will make a total of 11 visits to the clinic, and will be required to participate in a follow-up telephone call 14 days after last dose of the study drug for adverse event assessment.

03

Conditions studied

  • Essential Hypertension

Keywords

  • Essential Hypertension
  • Hypertensive
  • Blood Pressure, High
  • Vascular Disease
  • Cardiovascular Disease
  • Drug Therapy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. 190 mm Hg on Day -1 or if the participant has not received antihypertensive treatment within 28 days before screening and has a mean sitting clinic systolic blood pressure greater than or equal to 160 and less than or equal to 190 mm Hg at the Screening Visit and on Day -1.
  2. Females of who are sexually active must agree to use adequate , and can neither be pregnant nor lactating from Screening throughout the duration of the study.
  3. Has clinical laboratory test results within the reference range for the testing laboratory or the investigator does not consider the results to be .
  4. Is willing to discontinue current antihypertensive medications on Day -21 or on Day -28 if is on amlodipine or chlorthalidone.

Exclusion criteria

Exclusion Criteria:

  1. Has a mean sitting clinic diastolic blood pressure greater than 119 mm Hg.
  2. Has a baseline 24-hour ambulatory blood pressure monitoring reading of insufficient quality.
  3. Works a night (third) shift (from 11 PM [2300] to 7 AM [0700]).
  4. Has an upper arm circumference less than 24 cm or greater than 42 cm.
  5. Is noncompliant with study medication during the placebo run-in period.
  6. Has secondary hypertension of any etiology.
  7. Has a recent history of myocardial infarction, heart failure, unstable angina, coronary artery bypass graft, percutaneous coronary intervention, hypertensive encephalopathy, cerebrovascular accident or .
  8. Has a cardiac conduction.
  9. Has hemodynamically significant left ventricular outflow obstruction due to aortic valvular disease.
  10. Has severe renal dysfunction or disease.
  11. Has a known or suspected unilateral or bilateral renal artery stenosis.
  12. Has a history of cancer that has not been in remission for at least 5 years prior to the first dose of study drug.
  13. Has poorly controlled type 1 or type 2 diabetes mellitus.
  14. Has hypokalemia or hyperkalemia.
  15. Has an or aspartate aminotransferase level of greater than 2.5 times the , active liver disease or jaundice.
  16. Has any other known serious disease or condition that would compromise safety, might affect or make it difficult to successfully manage and follow the participant according to the protocol.
  17. Has a known to angiotensin II receptor blockers or thiazide-type diuretics or other sulfonamide-derived compounds.
  18. Has been randomized in a previous Azilsartan Medoxomil study.
  19. Is currently participating in another study or has participated in an investigational study or is receiving or has received any investigational compound within 30 days prior to Randomization.
  20. Has a history of drug abuse or a history of alcohol abuse within the past 2 years.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
1,085 participants (actual)

Study arms

  • Experimental
    Azilsartan Medoxomil 20-40mg plus Chlorthalidone 12.5-25 mg QD

    (dependant on blood pressure)

    Drug: Azilsartan medoxomil and chlorthalidone

  • Experimental
    Azilsartan Medoxomil 40-80mg plus Chlorthalidone 12.5-25 mg QD

    (dependant on blood pressure)

    Drug: Azilsartan medoxomil and chlorthalidone

  • Active comparator
    Olmesartan medoxomil 20-40mg/hydrochlorothiazide 12.5-25mg QD

    (dependant on blood pressure)

    Drug: Olmesartan medoxomil-hydrochlorothiazide

Interventions

  • DrugAzilsartan medoxomil and chlorthalidone

    Drug pages: Azilsartan medoxomil · Chlorthalidone

    Azilsartan medoxomil 20 mg and chlorthalidone 12.5 mg, tablets, orally, and olmesartan medoxomil-hydrochlorothiazide placebo tablets once daily for 8 weeks. If participant does not achieve target blood pressure at Week 4, then the dosage will be increased to azilsartan medoxomil 40 mg and chlorthalidone 25 mg, tablets, orally, once daily for the remaining 4 weeks.

    Also known as: azilsartan medoxomil, chlorthalidone, TAK-491, TAK-491CLD

  • DrugAzilsartan medoxomil and chlorthalidone

    Drug pages: Azilsartan medoxomil · Chlorthalidone

    Azilsartan medoxomil 40 mg and chlorthalidone 12.5, mg, tablets, orally, and olmesartan medoxomil-hydrochlorothiazide placebo tablets once daily for 8 weeks. If participant does not achieve target blood pressure at Week 4, then the dosage will be increased to azilsartan medoxomil 80 mg and chlorthalidone 25 mg, tablets, orally, once daily for the remaining 4 weeks.

    Also known as: azilsartan medoxomil, chlorthalidone, TAK-491, TAK-491CLD

  • DrugOlmesartan medoxomil-hydrochlorothiazide

    Olmesartan medoxomil 20 mg/hydrochlorothiazide 12.5 mg, tablets, orally, and Azilsartan medoxomil and chlorthalidone placebo-matching tablets, orally, once daily for 8 weeks. If participant does not achieve target blood pressure at Week 4, then the dosage will be increased to olmesartan medoxomil 40 mg/hydrochlorothiazide 25 mg, tablets, orally, once daily for the remaining 4 weeks.

    Also known as: Benicar HCT®

06

What researchers measure

Primary outcomes

  1. Change From Baseline to Week 8 in Trough, Sitting, Clinic Systolic Blood Pressure.

    The change in trough systolic blood pressure measured at week 8 or final visit relative to baseline. Systolic blood pressure is the average of the 3 serial trough sitting systolic blood pressure measurements.

    Time frame: Baseline and Week 8.

Secondary outcomes

  1. Change From Baseline to Week 4 in Trough, Sitting, Clinic Systolic Blood Pressure.

    The change in trough systolic blood pressure measured at week 4 relative to baseline. Systolic blood pressure is the average of the 3 serial trough sitting systolic blood pressure measurements.

    Time frame: Baseline and Week 4.

  2. Change From Baseline in Trough, Sitting, Clinic Diastolic Blood Pressure

    The change in trough diastolic blood pressure measured at week 4 and week 8 relative to baseline. Diastolic blood pressure is the average of the 3 serial trough sitting diastolic blood pressure measurements.

    Time frame: Baseline, Week 4 and Week 8.

  3. Change From Baseline in Trough Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

    The change in trough systolic blood pressure measured at week 4 and week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Trough is the average of all measurements recorded from 22 to 24 hours after dosing.

    Time frame: Baseline, Week 4 and Week 8.

  4. Change From Baseline in Trough Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

    The change in trough systolic blood pressure measured at week 4 and week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Trough is the average of all measurements recorded from 22 to 24 hours after dosing.

    Time frame: Baseline, Week 4 and Week 8.

  5. Change From Baseline in 24-hour Mean Systolic Blood Pressure as Measured by Ambulatory Blood Pressure Monitoring.

    The change in the 24-hour mean systolic blood pressure at week4 and week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 24-hour mean is the average of all measurements recorded for 24 hours after dosing.

    Time frame: Baseline, Week 4 and Week 8.

  6. Change From Baseline in 24-hour Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

    The change in the 0 to 24-hours-after-dosing mean diastolic blood pressure measured at Week 4 and Week 8 relative to baseline. . Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The mean consists of the average of measurements collected over the subsequent 24 hours.

    Time frame: Baseline, Week 4 and Week 8.

  7. Change From Baseline in Daytime Mean (6am to 10pm) Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

    The change in the daytime, while awake (6am to 10pm) mean systolic blood pressure measured at Week 4 and Week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night Daytime mean is the average of measurements recorded between the hours of 6 AM (inclusive) and 10 PM (exclusive) included in the 24-hour mean calculations.

    Time frame: Baseline, Week 4 and Week 8.

  8. Change From Baseline in Daytime Mean (6am to 10pm) Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

    The change in the daytime, while awake (6am to 10pm) mean diastolic blood pressure measured at Week 4 and Week 8relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Daytime mean is the average of measurements recorded between the hours of 6 AM (inclusive) and 10 PM (exclusive) included in the 24-hour mean calculations.

    Time frame: Baseline, Week 4 and Week 8.

  9. Change From Baseline in Nighttime Mean (12am to 6am) Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring

    The change in the nighttime, while asleep (12am to 6am) mean systolic blood pressure measured at Week 4 and Week 8 to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Nighttime mean is the average of measurements recorded between the hours of 12 AM (inclusive) and 6 AM (exclusive) included in the 24-hour mean calculations.

    Time frame: Baseline, Week 4 and Week 8.

  10. Change From Baseline in Nighttime Mean (12am to 6am) Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

    The change in the nighttime, while asleep (12am to 6am) mean diastolic blood pressure measured at Week 4 and Week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Nighttime mean is the average (arithmetic mean) of measurements recorded between the hours of 12 AM (inclusive) and 6 AM (exclusive) included in the 24-hour mean calculations.

    Time frame: Baseline, Week 4 and Week 8.

  11. Change From Baseline in 12-hr Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

    The change in the 0 to 12 hours-after-dosing mean Systolic Blood Pressure measured at Week 4 and Week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night The mean consists of the average (arithmetic mean) of measurements collected at each time frame and includes all observations recorded over the subsequent 12 hours.

    Time frame: Baseline, Week 4 and Week 8.

  12. Change From Baseline in 12-hr Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

    The change in the 0 to 12 hours-after-dosing mean diastolic blood pressure measured at Week 4 and Week 8 to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The mean consists of the average (arithmetic mean) of measurements collected at each time frame and includes all observations recorded over the subsequent 12 hours.

    Time frame: Baseline, Week 4 and Week 8.

  13. Percentage of Participants Who Achieve a Clinic Systolic Blood Pressure Response, Defined as <140 mm Hg for Participants Without Diabetes or CKD or <130 mm Hg for Participants With Diabetes or CKD

    Percentage of participants who achieve a clinic systolic blood pressure response, defined as \<140 mm Hg for participants without diabetes or CKD or \<130 mm Hg for participants with diabetes or CKD at each time frame relative to baseline.

    Time frame: Baseline, Week 2, Week 4, Week 6 and Week 8.

  14. Percentage of Participants Who Achieve a Clinic Diastolic Blood Pressure Response, Defined as Defined as <90 mm Hg for Participants Without Diabetes or CKD or <80 mm Hg for Participants With Diabetes or CKD

    Percentage of participants who achieve a clinic diastolic blood pressure response, defined as defined as \<90 mm Hg for participants without diabetes or CKD or \<80 mm Hg for participants with diabetes or CKD at each time frame relative to baseline.

    Time frame: Baseline, Week 2, Week 4, Week 6 and Week 8.

  15. Percentage of Participants Who Achieve a Clinic Diastolic AND Systolic Blood Pressure Response, Defined as <140/90 mm Hg for Participants Without Diabetes or Chronic Kidney Disease (CKD) or <130/80 mm Hg for Participants With Diabetes or CKD

    Percentage of participants who achieve both a clinic diastolic blood pressure response, defined as \<140/90 mm Hg for participants without diabetes or chronic kidney disease (CKD) or \<130/80 mm Hg for participants with diabetes or CKD at each time frame relative to baseline.

    Time frame: Baseline, Week 2, Week 4, Week 6 and Week 8.

07

Results

Posted Mar 13, 2012

Participant flow

Participants enrolled at 93 investigative sites in Argentina, Chile, Mexico and the United States from 13 March 2009 to 25 June 2010.

Participant flow — Overall Study
MilestoneAzilsartan Medoxomil 20-40mg Plus Chlorthalidone 12.5-25 mg QDAzilsartan Medoxomil 40-80mg Plus Chlorthalidone 12.5-25 mg QDOlmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD
Started372357356
Completed317308323
Not completed554933
Withdrew: Adverse event203011
Withdrew: Protocol violation540
Withdrew: Lost to follow-up825
Withdrew: Withdrawal by subject11119
Withdrew: Pregnancy100
Withdrew: Lack of efficacy112
Withdrew: Other916

Outcome measures

PrimaryChange From Baseline to Week 8 in Trough, Sitting, Clinic Systolic Blood Pressure.

The change in trough systolic blood pressure measured at week 8 or final visit relative to baseline. Systolic blood pressure is the average of the 3 serial trough sitting systolic blood pressure measurements.

Time frame:
Baseline and Week 8.
Reported as:
Least squares mean · mmHg
Change From Baseline to Week 8 in Trough, Sitting, Clinic Systolic Blood Pressure.
mmHgAzilsartan Medoxomil 20-40mg Plus Chlorthalidone 12.5-25 mg QDAzilsartan Medoxomil 40-80mg Plus Chlorthalidone 12.5-25 mg QDOlmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD
Change From Baseline to Week 8 in Trough, Sitting, Clinic Systolic Blood Pressure.-37.6 ± 0.83-38.2 ± 0.85-31.5 ± 0.84
Statistical analysis
  • Azilsartan Medoxomil 20-40mg Plus Chlorthalidone 12.5-25 mg QD vs Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD · ANCOVA · p = <0.001 (Statistical significance was set at the 0.05 level per the predefined stepwise testing strategy used.) · Mean difference (final values): -6.1 · 95% CI -8.4 to -3.8
  • Azilsartan Medoxomil 40-80mg Plus Chlorthalidone 12.5-25 mg QD vs Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD · ANCOVA · p = <0.001 (Statistical significance was set at the 0.05 level per the predefined stepwise testing strategy used.) · Mean difference (final values): -6.7 · 95% CI -9.1 to -4.4
SecondaryChange From Baseline to Week 4 in Trough, Sitting, Clinic Systolic Blood Pressure.

The change in trough systolic blood pressure measured at week 4 relative to baseline. Systolic blood pressure is the average of the 3 serial trough sitting systolic blood pressure measurements.

Time frame:
Baseline and Week 4.
Reported as:
Least squares mean · mmHg
Change From Baseline to Week 4 in Trough, Sitting, Clinic Systolic Blood Pressure.
mmHgAzilsartan Medoxomil 20-40mg Plus Chlorthalidone 12.5-25 mg QDAzilsartan Medoxomil 40-80mg Plus Chlorthalidone 12.5-25 mg QDOlmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD
Change From Baseline to Week 4 in Trough, Sitting, Clinic Systolic Blood Pressure.-33.0 ± 0.87-34.1 ± 0.88-26.9 ± 0.88
Statistical analysis
  • Azilsartan Medoxomil 20-40mg Plus Chlorthalidone 12.5-25 mg QD vs Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD · ANCOVA · p = <0.001 (Statistical significance was set at the 0.05 level per the predefined stepwise testing strategy used.) · Mean difference (final values): -6.1 · 95% CI -8.5 to -3.7
  • Azilsartan Medoxomil 40-80mg Plus Chlorthalidone 12.5-25 mg QD vs Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD · ANCOVA · p = <0.001 (Statistical significance was set at the 0.05 level per the predefined stepwise testing strategy used.) · Median difference (final values): -7.2 · 95% CI -9.6 to -4.8
SecondaryChange From Baseline in Trough, Sitting, Clinic Diastolic Blood Pressure

The change in trough diastolic blood pressure measured at week 4 and week 8 relative to baseline. Diastolic blood pressure is the average of the 3 serial trough sitting diastolic blood pressure measurements.

Time frame:
Baseline, Week 4 and Week 8.
Reported as:
Least squares mean · mmHg
Change From Baseline in Trough, Sitting, Clinic Diastolic Blood Pressure
mmHgAzilsartan Medoxomil 20-40mg Plus Chlorthalidone 12.5-25 mg QDAzilsartan Medoxomil 40-80mg Plus Chlorthalidone 12.5-25 mg QDOlmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD
Week 4 (n=360; n=347; n=352)-13.6 ± 0.49-14.2 ± 0.50-10.4 ± 0.49
Week 8 (n=363; n=350; n=353)-16.1 ± 0.47-16.5 ± 0.48-12.8 ± 0.48
SecondaryChange From Baseline in Trough Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

The change in trough systolic blood pressure measured at week 4 and week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Trough is the average of all measurements recorded from 22 to 24 hours after dosing.

Time frame:
Baseline, Week 4 and Week 8.
Reported as:
Least squares mean · mmHg
Change From Baseline in Trough Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
mmHgAzilsartan Medoxomil 20-40mg Plus Chlorthalidone 12.5-25 mg QDAzilsartan Medoxomil 40-80mg Plus Chlorthalidone 12.5-25 mg QDOlmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD
Week 4 (n=223; n=227; n=219)-22.4 ± 0.95-23.6 ± 0.94-17.4 ± 0.96
Week 8 (n=290; n=278; n=281)-24.9 ± 0.79-26.8 ± 0.81-19.6 ± 0.80
SecondaryChange From Baseline in Trough Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

The change in trough systolic blood pressure measured at week 4 and week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Trough is the average of all measurements recorded from 22 to 24 hours after dosing.

Time frame:
Baseline, Week 4 and Week 8.
Reported as:
Least squares mean · mmHg
Change From Baseline in Trough Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
mmHgAzilsartan Medoxomil 20-40mg Plus Chlorthalidone 12.5-25 mg QDAzilsartan Medoxomil 40-80mg Plus Chlorthalidone 12.5-25 mg QDOlmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD
Week 4 (n=223; n=227; n=219)-13.4 ± 0.66-14.6 ± 0.66-10.9 ± 0.67
Week 8 (n=290; n=278; n=281)-14.6 ± 0.56-15.9 ± 0.57-12.0 ± 0.57
SecondaryChange From Baseline in 24-hour Mean Systolic Blood Pressure as Measured by Ambulatory Blood Pressure Monitoring.

The change in the 24-hour mean systolic blood pressure at week4 and week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 24-hour mean is the average of all measurements recorded for 24 hours after dosing.

Time frame:
Baseline, Week 4 and Week 8.
Reported as:
Least squares mean · mmHg
Change From Baseline in 24-hour Mean Systolic Blood Pressure as Measured by Ambulatory Blood Pressure Monitoring.
mmHgAzilsartan Medoxomil 20-40mg Plus Chlorthalidone 12.5-25 mg QDAzilsartan Medoxomil 40-80mg Plus Chlorthalidone 12.5-25 mg QDOlmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD
Week 4 (n=223; n=227; n=219)-24.1 ± 0.81-24.4 ± 0.80-18.4 ± 0.81
Week 8 (n=290; n=278; n=281)-26.4 ± 0.69-27.9 ± 0.70-20.7 ± 0.70
Statistical analysis
  • Azilsartan Medoxomil 20-40mg Plus Chlorthalidone 12.5-25 mg QD vs Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD · ANCOVA · p = <0.001 (Tested at the 0.05 significance level.) · Mean difference (final values): -5.6 · 95% CI -7.5 to -3.7
  • Azilsartan Medoxomil 40-80mg Plus Chlorthalidone 12.5-25 mg QD vs Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD · ANCOVA · p = <0.001 (Tested at the 0.05 significance level.) · Mean difference (final values): -7.2 · 95% CI -9.1 to -5.2
SecondaryChange From Baseline in 24-hour Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

The change in the 0 to 24-hours-after-dosing mean diastolic blood pressure measured at Week 4 and Week 8 relative to baseline. . Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The mean consists of the average of measurements collected over the subsequent 24 hours.

Time frame:
Baseline, Week 4 and Week 8.
Reported as:
Least squares mean · mmHg
Change From Baseline in 24-hour Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
mmHgAzilsartan Medoxomil 20-40mg Plus Chlorthalidone 12.5-25 mg QDAzilsartan Medoxomil 40-80mg Plus Chlorthalidone 12.5-25 mg QDOlmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD
Week 4 (n=223; n=227; n=219)-13.9 ± 0.51-14.4 ± 0.51-10.5 ± 0.52
Week 8 (n=290; n=278; n=281)-15.1 ± 0.45-16.4 ± 0.46-12.0 ± 0.46
SecondaryChange From Baseline in Daytime Mean (6am to 10pm) Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

The change in the daytime, while awake (6am to 10pm) mean systolic blood pressure measured at Week 4 and Week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night Daytime mean is the average of measurements recorded between the hours of 6 AM (inclusive) and 10 PM (exclusive) included in the 24-hour mean calculations.

Time frame:
Baseline, Week 4 and Week 8.
Reported as:
Least squares mean · mmHg
Change From Baseline in Daytime Mean (6am to 10pm) Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
mmHgAzilsartan Medoxomil 20-40mg Plus Chlorthalidone 12.5-25 mg QDAzilsartan Medoxomil 40-80mg Plus Chlorthalidone 12.5-25 mg QDOlmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD
Week 4 (n=223; n=227; n=219)-24.5 ± 0.84-25.1 ± 0.83-18.9 ± 0.85
Week 8 (n=290; n=278; n=281)-26.7 ± 0.72-28.4 ± 0.74-21.0 ± 0.74
SecondaryChange From Baseline in Daytime Mean (6am to 10pm) Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

The change in the daytime, while awake (6am to 10pm) mean diastolic blood pressure measured at Week 4 and Week 8relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Daytime mean is the average of measurements recorded between the hours of 6 AM (inclusive) and 10 PM (exclusive) included in the 24-hour mean calculations.

Time frame:
Baseline, Week 4 and Week 8.
Reported as:
Least squares mean · mmHg
Change From Baseline in Daytime Mean (6am to 10pm) Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
mmHgAzilsartan Medoxomil 20-40mg Plus Chlorthalidone 12.5-25 mg QDAzilsartan Medoxomil 40-80mg Plus Chlorthalidone 12.5-25 mg QDOlmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD
Week 4 (n=223; n=227; n=219)-14.2 ± 0.53-14.7 ± 0.53-10.7 ± 0.54
Week 8 (n=290; n=278; n=281)-15.3 ± 0.47-16.6 ± 0.48-12.1 ± 0.48
SecondaryChange From Baseline in Nighttime Mean (12am to 6am) Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring

The change in the nighttime, while asleep (12am to 6am) mean systolic blood pressure measured at Week 4 and Week 8 to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Nighttime mean is the average of measurements recorded between the hours of 12 AM (inclusive) and 6 AM (exclusive) included in the 24-hour mean calculations.

Time frame:
Baseline, Week 4 and Week 8.
Reported as:
Least squares mean · mmHg
Change From Baseline in Nighttime Mean (12am to 6am) Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring
mmHgAzilsartan Medoxomil 20-40mg Plus Chlorthalidone 12.5-25 mg QDAzilsartan Medoxomil 40-80mg Plus Chlorthalidone 12.5-25 mg QDOlmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD
Week 4 (n=223; n=227; n=219)-22.3 ± 0.87-21.9 ± 0.86-16.6 ± 0.88
Week 8 (n=290; n=278; n=281)-25.2 ± 0.74-26.3 ± 0.75-19.7 ± 0.75
SecondaryChange From Baseline in Nighttime Mean (12am to 6am) Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

The change in the nighttime, while asleep (12am to 6am) mean diastolic blood pressure measured at Week 4 and Week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Nighttime mean is the average (arithmetic mean) of measurements recorded between the hours of 12 AM (inclusive) and 6 AM (exclusive) included in the 24-hour mean calculations.

Time frame:
Baseline, Week 4 and Week 8.
Reported as:
Least squares mean · mmHg
Change From Baseline in Nighttime Mean (12am to 6am) Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
mmHgAzilsartan Medoxomil 20-40mg Plus Chlorthalidone 12.5-25 mg QDAzilsartan Medoxomil 40-80mg Plus Chlorthalidone 12.5-25 mg QDOlmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD
Week 4 (n=223; n=227; n=219)-13.4 ± 0.58-13.3 ± 0.58-9.6 ± 0.59
Week 8 (n=290; n=278; n=281)-14.9 ± 0.51-15.8 ± 0.52-11.8 ± 0.52
SecondaryChange From Baseline in 12-hr Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

The change in the 0 to 12 hours-after-dosing mean Systolic Blood Pressure measured at Week 4 and Week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night The mean consists of the average (arithmetic mean) of measurements collected at each time frame and includes all observations recorded over the subsequent 12 hours.

Time frame:
Baseline, Week 4 and Week 8.
Reported as:
Least squares mean · mmHg
Change From Baseline in 12-hr Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
mmHgAzilsartan Medoxomil 20-40mg Plus Chlorthalidone 12.5-25 mg QDAzilsartan Medoxomil 40-80mg Plus Chlorthalidone 12.5-25 mg QDOlmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD
Week 4 (n=223; n=227; n=219)-25.0 ± 0.87-25.5 ± 0.86-19.2 ± 0.88
Week 8 (n=290; n=278; n=281)-27.1 ± 0.77-28.8 ± 0.78-21.1 ± 0.78
SecondaryChange From Baseline in 12-hr Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

The change in the 0 to 12 hours-after-dosing mean diastolic blood pressure measured at Week 4 and Week 8 to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The mean consists of the average (arithmetic mean) of measurements collected at each time frame and includes all observations recorded over the subsequent 12 hours.

Time frame:
Baseline, Week 4 and Week 8.
Reported as:
Least squares mean · mmHg
Change From Baseline in 12-hr Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
mmHgAzilsartan Medoxomil 20-40mg Plus Chlorthalidone 12.5-25 mg QDAzilsartan Medoxomil 40-80mg Plus Chlorthalidone 12.5-25 mg QDOlmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD
Week 4 (n=223; n=227; n=219)-14.4 ± 0.56-14.8 ± 0.55-10.8 ± 0.56
Week 8 (n=290; n=278; n=281)-15.4 ± 0.50-16.9 ± 0.51-12.1 ± 0.51
SecondaryPercentage of Participants Who Achieve a Clinic Systolic Blood Pressure Response, Defined as <140 mm Hg for Participants Without Diabetes or CKD or <130 mm Hg for Participants With Diabetes or CKD

Percentage of participants who achieve a clinic systolic blood pressure response, defined as \<140 mm Hg for participants without diabetes or CKD or \<130 mm Hg for participants with diabetes or CKD at each time frame relative to baseline.

Time frame:
Baseline, Week 2, Week 4, Week 6 and Week 8.
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieve a Clinic Systolic Blood Pressure Response, Defined as <140 mm Hg for Participants Without Diabetes or CKD or <130 mm Hg for Participants With Diabetes or CKD
percentage of participantsAzilsartan Medoxomil 20-40mg Plus Chlorthalidone 12.5-25 mg QDAzilsartan Medoxomil 40-80mg Plus Chlorthalidone 12.5-25 mg QDOlmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD
Week 2 (n=343; n=334; n=345)60.357.244.9
Week 4 (n=360; n=347; n=352)66.168.952.3
Week 6 (n=362; n=350; n=353)76.873.464.9
Week 8 (n=363; n=350; n=353)76.076.064.6
SecondaryPercentage of Participants Who Achieve a Clinic Diastolic Blood Pressure Response, Defined as Defined as <90 mm Hg for Participants Without Diabetes or CKD or <80 mm Hg for Participants With Diabetes or CKD

Percentage of participants who achieve a clinic diastolic blood pressure response, defined as defined as \<90 mm Hg for participants without diabetes or CKD or \<80 mm Hg for participants with diabetes or CKD at each time frame relative to baseline.

Time frame:
Baseline, Week 2, Week 4, Week 6 and Week 8.
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieve a Clinic Diastolic Blood Pressure Response, Defined as Defined as <90 mm Hg for Participants Without Diabetes or CKD or <80 mm Hg for Participants With Diabetes or CKD
percentage of participantsAzilsartan Medoxomil 20-40mg Plus Chlorthalidone 12.5-25 mg QDAzilsartan Medoxomil 40-80mg Plus Chlorthalidone 12.5-25 mg QDOlmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD
Week 2 (n=343; n=334; n=345)63.666.247.8
Week 4 (n=360; n=347; n=352)71.473.858.2
Week 6 (n=362; n=350; n=353)77.976.966.9
Week 8 (n=363; n=350; n=353)79.979.166.0
SecondaryPercentage of Participants Who Achieve a Clinic Diastolic AND Systolic Blood Pressure Response, Defined as <140/90 mm Hg for Participants Without Diabetes or Chronic Kidney Disease (CKD) or <130/80 mm Hg for Participants With Diabetes or CKD

Percentage of participants who achieve both a clinic diastolic blood pressure response, defined as \<140/90 mm Hg for participants without diabetes or chronic kidney disease (CKD) or \<130/80 mm Hg for participants with diabetes or CKD at each time frame relative to baseline.

Time frame:
Baseline, Week 2, Week 4, Week 6 and Week 8.
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieve a Clinic Diastolic AND Systolic Blood Pressure Response, Defined as <140/90 mm Hg for Participants Without Diabetes or Chronic Kidney Disease (CKD) or <130/80 mm Hg for Participants With Diabetes or CKD
percentage of participantsAzilsartan Medoxomil 20-40mg Plus Chlorthalidone 12.5-25 mg QDAzilsartan Medoxomil 40-80mg Plus Chlorthalidone 12.5-25 mg QDOlmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD
Week 2 (n=343; n=334; n=345)51.348.535.9
Week 4 (n=360; n=347; n=352)58.161.444.6
Week 6 (n=362; n=350; n=353)68.865.455.5
Week 8 (n=363; n=350; n=353)69.468.954.7

Adverse events

Collected over Treatment-emergent adverse events are adverse events that started on or after the first dose of double-blind study drug and no more than 14 days (or 30 days for a serious adverse event) after the last dose of double-blind study drug.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Azilsartan Medoxomil 20-40mg Plus Chlorthalidone 12.5-25 mg QD—4/372 (1.1%)66/372 (17.7%)
Azilsartan Medoxomil 40-80mg Plus Chlorthalidone 12.5-25 mg QD—8/357 (2.2%)72/357 (20.2%)
Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD—6/356 (1.7%)56/356 (15.7%)
Most frequent serious events
Showing 10 of 27
Most frequent serious events
EventAzilsartan Medoxomil 20-40mg Plus Chlorthalidone 12.5-25 mg QDAzilsartan Medoxomil 40-80mg Plus Chlorthalidone 12.5-25 mg QDOlmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD
Cardiac arrestCardiac disorders0/3721/3571/356
Coronary artery diseaseCardiac disorders0/3720/3571/356
Chest painGeneral disorders0/3720/3571/356
Systemic inflammatory response syndromeGeneral disorders0/3720/3571/356
CellulitisInfections and infestations0/3721/3571/356
Heat exhaustionInjury, poisoning and procedural complications0/3720/3571/356
Troponin increasedInvestigations0/3720/3571/356
DehydrationMetabolism and nutrition disorders0/3720/3571/356
Pulmonary embolismRespiratory, thoracic and mediastinal disorders1/3720/3571/356
AsthmaRespiratory, thoracic and mediastinal disorders0/3720/3571/356
Most frequent other events
Most frequent other events
EventAzilsartan Medoxomil 20-40mg Plus Chlorthalidone 12.5-25 mg QDAzilsartan Medoxomil 40-80mg Plus Chlorthalidone 12.5-25 mg QDOlmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD
Blood creatinine increasedInvestigations36/37244/35725/356
DizzinessNervous system disorders25/37224/35720/356
HeadacheNervous system disorders14/37214/35718/356

Baseline characteristics

Age Continuous
Age Continuous(years)Azilsartan Medoxomil 20-40mg Plus Chlorthalidone 12.5-25 mg QDAzilsartan Medoxomil 40-80mg Plus Chlorthalidone 12.5-25 mg QDOlmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QDTotal
Mean55.5 ± 10.4956.7 ± 10.8355.7 ± 9.7856.0 ± 10.38
Age, Customized
Age, Customized(participants)Azilsartan Medoxomil 20-40mg Plus Chlorthalidone 12.5-25 mg QDAzilsartan Medoxomil 40-80mg Plus Chlorthalidone 12.5-25 mg QDOlmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QDTotal
<45 years473841126
45 to 64 years252244249745
≥65 years737566214
Sex: Female, Male
Sex: Female, Male(Participants)Azilsartan Medoxomil 20-40mg Plus Chlorthalidone 12.5-25 mg QDAzilsartan Medoxomil 40-80mg Plus Chlorthalidone 12.5-25 mg QDOlmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QDTotal
Female175174173522
Male197183183563
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Azilsartan Medoxomil 20-40mg Plus Chlorthalidone 12.5-25 mg QDAzilsartan Medoxomil 40-80mg Plus Chlorthalidone 12.5-25 mg QDOlmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QDTotal
Hispanic or Latino374144122
Not Hispanic or Latino265253251769
Unknown or Not Reported706361194
Race (NIH/OMB)
Race (NIH/OMB)(participants)Azilsartan Medoxomil 20-40mg Plus Chlorthalidone 12.5-25 mg QDAzilsartan Medoxomil 40-80mg Plus Chlorthalidone 12.5-25 mg QDOlmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QDTotal
American Indian or Alaska Native373435106
Asian75517
Native Hawaiian or Other Pacific Islander3003
Black or African American9595100290
White235225220680
More than one race52411
Unknown or Not Reported0000
Region of Enrollment
Region of Enrollment(participants)Azilsartan Medoxomil 20-40mg Plus Chlorthalidone 12.5-25 mg QDAzilsartan Medoxomil 40-80mg Plus Chlorthalidone 12.5-25 mg QDOlmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QDTotal
United States302294295891
Mexico454443132
Chile1210931
Argentina139931
Weight
Weight(kg)Azilsartan Medoxomil 20-40mg Plus Chlorthalidone 12.5-25 mg QDAzilsartan Medoxomil 40-80mg Plus Chlorthalidone 12.5-25 mg QDOlmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QDTotal
Mean89.35 ± 20.99589.87 ± 21.28190.66 ± 20.70089.95 ± 20.981
Height
Height(cm)Azilsartan Medoxomil 20-40mg Plus Chlorthalidone 12.5-25 mg QDAzilsartan Medoxomil 40-80mg Plus Chlorthalidone 12.5-25 mg QDOlmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QDTotal
Mean167.5 ± 11.22167.8 ± 11.06168.2 ± 10.30167.8 ± 10.87

4 further baseline measures are reported on the registry.

08

Study locations

80 sites
  • Birmingham, Alabama, United States
  • Haleyville, Alabama, United States
  • Hueytown, Alabama, United States
  • Jasper, Alabama, United States
  • Tallassee, Alabama, United States
  • Green Valley, Arizona, United States
  • Phoenix, Arizona, United States
  • Long Beach, California, United States
  • National City, California, United States
  • Roseville, California, United States
  • San Francisco, California, United States
  • San Jose, California, United States
  • Newark, Delaware, United States
  • Clearwater, Florida, United States
  • Jacksonville, Florida, United States
  • Jupiter, Florida, United States
  • Miami, Florida, United States
  • Ocala, Florida, United States
  • Pembroke Pines, Florida, United States
  • Plant City, Florida, United States
  • Tallahassee, Florida, United States
  • Arlington Heights, Illinois, United States
  • Chicago, Illinois, United States
  • Gurnee, Illinois, United States
  • Avon, Indiana, United States
  • Wichita, Kansas, United States
  • Louisville, Kentucky, United States
  • Auburn, Maine, United States
  • Baltimore, Maryland, United States
  • Brockton, Massachusetts, United States
  • Haverhill, Massachusetts, United States
  • North Dartmouth, Massachusetts, United States
  • Bingham Farms, Michigan, United States
  • Stevensville, Michigan, United States
  • Olive Branch, Mississippi, United States
  • Kansas City, Missouri, United States
  • New York, New York, United States
  • Burlington, North Carolina, United States
  • Charlotte, North Carolina, United States
  • Hickory, North Carolina, United States
  • Shelby, North Carolina, United States
  • Akron, Ohio, United States
  • Cleveland, Ohio, United States
  • Columbus, Ohio, United States
  • Marion, Ohio, United States
  • Middleburg Heights, Ohio, United States
  • Willoughby Hills, Ohio, United States
  • Norman, Oklahoma, United States
  • Bensalem, Pennsylvania, United States
  • Erie, Pennsylvania, United States
  • Reading, Pennsylvania, United States
  • Cranston, Rhode Island, United States
  • Cumberland, Rhode Island, United States
  • North Charleston, South Carolina, United States
  • Jackson, Tennessee, United States
  • Kingsport, Tennessee, United States
  • Milan, Tennessee, United States
  • Austin, Texas, United States
  • Corpus Christi, Texas, United States
  • Dallas, Texas, United States
  • Houston, Texas, United States
  • San Antonio, Texas, United States
  • Salt Lake City, Utah, United States
  • Arlington, Virginia, United States
  • Burke, Virginia, United States
  • Charlottesville, Virginia, United States
  • Manassas, Virginia, United States
  • Lakewood, Washington, United States
  • Port Orchard, Washington, United States
  • Menomonee Falls, Wisconsin, United States
  • Temuco, Cautín, Chile
  • La Serena, Elqui, Chile
  • Vina del Mar, Valparaíso, Chile
  • Osorno, Chile
  • Santiago, Chile
  • Tijuana, Baja California, Mexico
  • Leon, Guanajuato, Mexico
  • Guadalajara, Jalisco, Mexico
  • Chihuahua, Mexico
  • San Luis Potosi, Mexico
09

References and documents

Publications

  • Cushman WC, Bakris GL, White WB, Weber MA, Sica D, Roberts A, Lloyd E, Kupfer S. A randomized titrate-to-target study comparing fixed-dose combinations of azilsartan medoxomil and chlorthalidone with olmesartan and hydrochlorothiazide in stage-2 systolic hypertension. J Hypertens. 2018 Apr;36(4):947-956. doi: 10.1097/HJH.0000000000001647. PubMed 29334491 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2009, a primary completion of Jun 2010 and a completion of Jun 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2012, 1 year 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 13, 2009
First posted
Feb 18, 2009
Start
Mar 2009
Primary completionActual
Jun 2010
CompletionActual
Jun 2010
Results first posted
Mar 13, 2012
Last update
Mar 13, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 13, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00846365
Lead sponsor
Takeda
Responsible party
Sponsor
First posted
Feb 18, 2009
Start date
Mar 2009
Primary completion
Jun 2010
Completion
Jun 2010
Results posted
Mar 13, 2012
Last update
Mar 13, 2012

Study contacts

Executive Medical Director
study director · Takeda

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Azilsartan medoxomil · Chlorthalidone

Start the discussion